We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Nova Biomedical

Nova is a world leader in the development and manufacturing of whole blood, point-of-care and critical care analyzers... read more Featured Products: More products

Download Mobile App





Nova Biomedical Presents POC and Critical Care Whole Blood IVD Testing Solutions

By LabMedica International staff writers
Posted on 13 Nov 2023
Print article
Image: Nova Biomedical is exhibiting at MEDICA 2023 at Hall 3/ C16-2 (Photo courtesy of Nova Biomedical)
Image: Nova Biomedical is exhibiting at MEDICA 2023 at Hall 3/ C16-2 (Photo courtesy of Nova Biomedical)

Nova Biomedical (Waltham, MA, USA) is presenting its range of point of care (POC) and critical care whole blood in vitro diagnostic testing solutions at MEDICA 2023.

Nova Biomedical is demonstrating the Stat Profile Prime Plus Critical Care analyzer which recently received the U.S. Food and Drug Administration (FDA) 510(k) clearance for a microcapillary sample mode. Prime Plus now performs an 11-test panel including pH, PCO2, PO2, Na, K, iCa, iMg, Cl, glucose, lactate, and hematocrit with just 90 microliters of capillary blood, or a complete 22-test profile on just 135 microliters of blood. The use of small-volume microcapillary blood collection tubes with Prime Plus eliminates sample over-draws, dead volume, and sample waste from syringe or vacuum tube devices. Prime Plus comprehensive test menu enables scheduled bundling of tests to eliminate multiple sample draws, use of multiple sample containers, and amount of blood drawn for critical care testing.

Nova Biomedical’s StatStrip Glucose Hospital Meter System is also being exhibited at MEDICA 2023. The StatStrip Glucose and StatStrip Glucose/Ketone meters are specifically designed for the detection and management of dysglycemia throughout all professional healthcare settings including critical care. Also on display at the event are the StatStrip and StatStrip Xpress2 Lactate, Hemoglobin, and Hematocrit Meter Systems which provide lactate results in only 13 seconds from a 0.6 microliter capillary blood sample, and hemoglobin and hematocrit results in 40 seconds from a 1.6 microliter capillary blood sample. StatStrip Lac/Hb/Hct meter system can connect to laboratory information systems (LIS) and electronic medical records (EMR) while the Xpress2 Lac/Hb/Hct is designed for applications that do not require connectivity.

All results offer excellent correlation to laboratory reference methods and testing with a StatStrip or Xpress2 Lac/Hb/Hct meter system is as easy as glucose self-testing. StatStrip and StatStrip Xpress2 Lac/Hb/Hct systems offer fast, point-of-care (POC) testing with single-use, disposable biosensors, tiny capillary blood samples, and easy-to-read, color display screens. The meters enable rapid, affordable lactate, hemoglobin, and hematocrit testing for any size emergency department, intensive care unit, or medical unit, as well as in pre-hospital, ambulance, and military care situations.

Related Links:
Nova Biomedical 

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System
New
Ultrasonic Cleaner
UC 300 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.